I posted on this a few months ago. The recruiting rate for this trial is just under 1 patient randomised (dosed) per site per year. Trafere FSG sparsentan trial in same population was 0.6 patients randomised per site per year. That’s published. The maths is simple, and it doesn’t lie.
/// so if you know how many live participating hospitals there are in the trial you can reasonably reliably estimate progress.
Ann: Investor Presentation, page-141
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.0¢ |
Change
-0.030(5.45%) |
Mkt cap ! $299.6M | |||
| Open | High | Low | Value | Volume |
| 54.5¢ | 55.5¢ | 51.5¢ | $1.461M | 2.739M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 31651 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.5¢ | 67293 | 5 |
View Market Depth
| Last trade - 13.10pm 24/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |